Abstract: The present technology is directed to adjustable shunts for treating glaucoma. In particular, some embodiments provide shunts having a plurality of individually actuatable flow control elements that can control the flow of fluid through associated ports and/or flow lumens. For example, each individually actuatable flow control element can be actuated to block and/or unblock a corresponding port and/or flow lumen. Accordingly, the shunts described herein can be manipulated into a variety of configurations that provide different drainage rates based on whether the ports and/or flow lumens are blocked or unblocked, therefore providing a titratable glaucoma therapy for draining aqueous from the anterior chamber of the eye.

Abstract: A device for treating a diseased native valve in a patient includes a frame structure and a valve segment coupled to the frame structure. The frame structure has an unexpanded configuration and an expanded configuration. The valve segment has a plurality of leaflets, a seal, and a seal support. An inflow edge of the plurality of leaflets is unsupported by the frame structure. The seal is attached to the inflow edge of the plurality of leaflets and positioned radially between the frame structure and the plurality of leaflets. The seal support is attached to or within the seal and provides axial rigidity to the seal.

Abstract: An accommodating intraocular lens (AIOL) for implantation within a capsular bag of a patient's eye comprises first and second components coupled together to define an inner fluid chamber and an outer fluid reservoir. The inner region of the AIOL provides optical power with one or more of the shaped fluid within the inner fluid chamber or the shape of the first or second components. The fluid reservoir comprises a bellows region with fold(s) extending circumferentially around an optical axis of the eye. The bellows engages the lens capsule, and a compliant fold region between inner and outer bellows portions allows the profile of the AIOL to deflect when the eye accommodates for near vision. Fluid transfers between the inner fluid chamber and the outer fluid reservoir to provide optical power changes. A third lens component coupled to the first or second component provides additional optical power.

Abstract: Systems, devices, and methods for treating a diseased native valve in a patient, the system comprising a compressible and expandable frame structure and an anchor. The anchor comprises a wire having a free end and is configured to be fully advanced from an atrial side of a native valve in a patient into a ventricle of the heart and anchor the frame structure to the native valve when the frame structure is in the expanded configuration adjacent the native valve.

Abstract: A system for treating a diseased native valve in a patient, the system comprising a compressible and expandable frame structure with an expanded configuration comprising one or more anchor retaining elements disposed along one or more lateral sides of the frame structure, and one or more anchors having a free end. In one embodiment, the anchors are slidably disposed within the one or more anchor retaining elements of the frame structure and can be configured to be releasably attached to one or more proximal anchor pusher elements disposed within an inner shaft of a delivery device.

Abstract: A heart valve prosthesis for replacing a diseased native valve in a patient, the valve includes an expandable frame structure and an anchor. The anchor comprises a free end and has a flat spiral shape. The anchor comprises a housing, a lumen disposed within the housing, and a plurality of spiral bands translatably disposed within the housing. The valve may further include a valve segment mounted within the frame structure and expanded with the frame structure. The frame structure may be configured for receiving a valve segment.

Abstract: In particular, some embodiments provide shunts having a plurality of individually actuatable flow control elements that can control the flow of fluid through associated ports and/or flow lumens. For example, each individually actuatable flow control element can be actuated to modify a flow of a corresponding port and/or flow lumen. The individually actuatable flow control elements may be actuated along a given actuation axis. A flow control assembly may include a plurality of flow control elements arranged about a collection region. Accordingly, the shunts described herein can be manipulated into a variety of configurations that provide different drainage rates based on a degree to which the ports and/or flow lumens are blocked or unblocked, therefore providing a titratable glaucoma therapy for draining aqueous from the anterior chamber of the eye.

Abstract: The present technology relates to adjustable shunting systems and methods. In some embodiments, the present technology includes an adjustable shunting system that includes a drainage element having an inflow portion configured for placement within a patient. The system can also include a flow control assembly having a gating element operably coupled to the outflow portion of the drainage element. The flow control assembly can further include a first actuation element and a second actuation element coupled to the gating element. The first and second actuation elements can be configured to selectively move the gating element relative to the outflow portion to control an amount of fluid flow therethrough. The first and second actuation elements can each extend less than entirely around a perimeter of the drainage element.

Abstract: The present technology is directed to implantable medical devices for draining fluid from a first body region to a second body region. Some embodiments of the present technology provide adjustable devices that are selectively titratable to provide various levels of therapy. For example, the adjustable devices can have a drainage element with a lumen extending therethrough, a flow control element, and an actuation assembly. The actuation assembly can drive movement of the flow control element to change a dimension of and/or a flow resistance through the lumen, thereby increasing or decreasing the relative drainage rate of aqueous from an eye. In some embodiments, the actuation assembly and the flow control element together operate as a ratchet mechanism that can selectively move the flow control element between a plurality of positions and lock the device in a desired configuration until further actuation of the actuation assembly.

Abstract: The present technology is directed to an adjustable power intraocular lens comprising a container, an optical fluid in the container, and a transport substance in solution with the optical fluid. The container has an optical component and a peripheral component extending around at least a portion of the optical component. The optical component has an anterior optical element, a posterior optical element, and a fluid chamber having a chamber volume between the anterior optical element and the posterior optical element. The transport substance is configured to pass through the container. The adjustable power intraocular lens further comprises volume control elements in the container. The volume control elements are configured to be activated by a non-invasive energy and upon activation release the transport substance into the optical fluid to decrease the chamber volume and/or absorb the transport substance from the optical fluid to increase the chamber volume.

Abstract: The present technology is directed to adjustable shunts for treating glaucoma. In particular, some embodiments provide shunts having a plurality of individually actuatable flow control elements that can control the flow of fluid through associated ports and/or flow lumens. For example, each individually actuatable flow control element can be actuated to block and/or unblock a corresponding port and/or flow lumen. Accordingly, the shunts described herein can be manipulated into a variety of configurations that provide different drainage rates based on whether the ports and/or flow lumens are blocked or unblocked, therefore providing a titratable glaucoma therapy for draining aqueous from the anterior chamber of the eye.

Abstract: The present technology is directed to adjustable flow glaucoma shunts, systems, and methods for making and using such devices. In many of the embodiments described herein, the shunts include a drainage element configured to fluidly couple an anterior chamber of an eye and a target outflow location, such as a subconjunctival bleb space. The shunts can further include a flow control assembly coupled to the drainage element and configured to control the flow of fluid (e.g., aqueous) therethrough. The shunts can further include an outer membrane or bladder that encases the flow control assembly. The outer membrane can include a plurality of apertures that fluidly couple an interior of the outer membrane with an environment exterior to the outer membrane.

Abstract: The present technology relates to intraocular shunting systems and methods. In some embodiments, the present technology includes intraocular shunting systems that include a drainage element having an inflow portion configured for placement within an anterior chamber of the eye outside of an optical field of view of the patient and an outflow portion configured for placement at a different location of the eye. The system can also include a flow control assembly having a rotational control element operably coupled to the drainage element. The flow control assembly can further include an actuation structure coupled to the rotational control element and configured to selectively change an orientation of the rotational control element. An amount of fluid through the inflow portion and/or the outflow portion can vary based on the selected orientation of the rotational control element.

Abstract: The present technology is directed to adjustable flow glaucoma shunts and methods for making and using such devices. In many of the embodiments described herein, the shunts include a generally flat frame. The frame can include an elongated portion having a lumen extending therethrough and a bladder portion defining an interior chamber that is in fluid communication with the lumen. When implanted in a patient's eye, aqueous can drain from the anterior chamber to a target outflow location via the lumen and interior chamber. In some embodiments, the shunts include a flow control assembly positioned within the interior chamber of the bladder portion to control the flow of aqueous through the lumen.

Abstract: The present technology is generally directed to interatrial shunting systems and associated devices and methods. For example, a system configured in accordance with embodiments of the present technology can include a shunting element implantable into a patient at or adjacent a septal wall. The shunting element can have a lumen that fluidly connects a left atrium and a right atrium of the patient to facilitate blood flow therebetween when the shunting element is implanted. In some embodiments, the system further includes a flow control element to selectively control blood flow between the left atrium and the right atrium.

Abstract: The present technology is directed to adjustable flow glaucoma shunts and methods for making and using such devices. In many of the embodiments described herein, the shunts include a generally flat frame. The frame can include an elongated portion having a lumen extending therethrough and a bladder portion defining an interior chamber that is in fluid communication with the lumen. When implanted in a patient's eye, aqueous can drain from the anterior chamber to a target outflow location via the lumen and interior chamber. In some embodiments, the shunts include a flow control assembly positioned within the interior chamber of the bladder portion to control the flow of aqueous through the lumen.

Abstract: A system for treating a diseased native valve in a patient includes a valve prosthesis and a delivery device. The prosthesis includes an anchor and a frame. The delivery device includes an outer sheath, an inner shaft, an anchor guide, and a tether. The anchor is shaped to encircle chordae or leaflets of a native valve. The frame is configured to sit within the anchor. The inner shaft is positioned within the outer sheath and translatable and rotatable relative to the outer sheath. The anchor guide is attached to a distal end of the inner shaft and has a curved distal section. The tether is configured to detachably couple to the anchor and to longitudinally translate the anchor within the inner shaft and anchor guide. The anchor is configured to be actuated from a delivery configuration to the deployed configuration when the anchor is translated out of the anchor guide.

Abstract: An accommodating intraocular lens (AIOL) can include an accommodating lens structure having an accommodating optical power. The AIOL can include a secondary structure removably connected to the accommodating lens. In some embodiments, the accommodating lens structure is configured to adjust the accommodating optical power in response to radial forces from the capsule of a patient. The secondary structure can be a sensor assembly, a powered lens and/or a light-adjustable lens. In some embodiments, the accommodating lens structure comprises an outer fluid reservoir and a fluid accommodating lens in fluid communication with the outer fluid reservoir. The outer fluid reservoir can be configured to transfer fluid into the fluid accommodating lens in reaction to compressive forces on the outer fluid reservoir.

Abstract: An accommodating intraocular lens (AIOL) for implantation within a capsular bag of a patient's eye comprises first and second components coupled together to define an inner fluid chamber and an outer fluid reservoir. The inner region of the AIOL provides optical power with one or more of the shaped fluid within the inner fluid chamber or the shape of the first or second components. The fluid reservoir comprises a bellows region with fold(s) extending circumferentially around an optical axis of the eye. The bellows engages the lens capsule, and a compliant fold region between inner and outer bellows portions allows the profile of the AIOL to deflect when the eye accommodates for near vision. Fluid transfers between the inner fluid chamber and the outer fluid reservoir to provide optical power changes. A third lens component coupled to the first or second component provides additional optical power.

Abstract: The present technology provides systems, devices, and methods for forming blebs to treat ocular hypertension or glaucoma. In some embodiments, a minimally invasive bleb formation device comprises an introducer sheath having a lumen extending longitudinally therethrough. The lumen has a distal end aperture insertable adjacent to a target tissue. The device further includes a wire positionable within the lumen of the introducer sheath. The wire has a first end portion, a second end portion, and an intermediate region between the first end portion and the second end portion. At least a segment of the intermediate portion is configured to extend through the distal end aperture to form a wire loop. The wire loop is moveable between a plurality of positions and is configured to disrupt and cauterize the target tissue.